Home - Intellia Therapeutics
Intellia Tx. Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics...
Read Intelliatx.com news digest here: view the latest Intellia Tx articles and content updates right away or get to their most visited pages. Intelliatx.com belongs to a large group of moderately popular websites, with around 15K visitors from all over the world monthly. It seems that Intellia Tx content is notably popular in USA, as 61.6% of all users (9.1K visits per month) come from this country. We haven’t detected security issues or inappropriate content on Intelliatx.com and thus you can safely use it. Intelliatx.com is hosted with WPEngine, Inc. (Spain) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
494
Visitors daily -
494
Pageviews daily -
N/A
Google PR -
245 432
Alexa rank
Best pages on Intelliatx.com
-
Intellia Therapeutics - Treating genetic disease at the cutting edge
Treating genetic disease at the cutting edge
-
Genome Editing Company Overview - Intellia Therapeutics
Using CRISPR/Cas9 genome editing breakthroughs, Intellia is developing gene therapies to cure multiple genetic diseases.
-
Pipeline - Intellia Therapeutics
We believe our approach to selecting our sentinel in vivo and ex vivo programs positions us to build a pipeline across a range of indications and to generate a wealth of data that opens the potential ...
Intelliatx.com news digest
-
6 years
Intellia Therapeutics to Present at October Healthcare Investor Conferences
CAMBRIDGE, Mass., October 3, 2017 — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare...
-
6 years
Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRI...
First-in-class, one-year data demonstrate sustained TTR protein reduction of approximately 97 percent, corresponding to 70 percent liver editing, following a single in vivo systemic dose in mice
Non-human primate studies ongoing and leading to development candidate designation in first half 2018... -
6 years
Intellia Therapeutics to Present at Upcoming September Investor Healthcare Confe...
CAMBRIDGE, Mass., September 7, 2017 — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at key September investor healthcare...
-
6 years
Intellia Therapeutics Announces Second Quarter 2017 Financial Results
In non-human primates, demonstrated robust green fluorescent protein expression throughout the liver 24 hours following a single, systemically delivered, intravenous dose, using our proprietary lipid nanoparticle delivery system
Using our proprietary lipid nanoparticle delivery system, demonstrated in vivo durable liver genome editing in mice through nine months, post-single-dose intravenous administration...
Domain history
| Web host: | WPEngine, Inc. |
| Registrar: | GoDaddy.com, LLC |
| Registrant: | Registration Private (Domains By Proxy, LLC) |
| Updated: | October 13, 2023 |
| Expires: | October 27, 2028 |
| Created: | May 23, 2014 |
Whois record
Safety scores
Trustworthiness
N/AChild safety
N/A
